Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: October 19, 2009
Event: Entry into a Material Definitive Agreement with Laboratorio Avi-Mex S.A. de C.V. ("Avimex").
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses on the terms of a new agreement rather than historical financial performance.
- Revenue Impact: Avimex made a fixed non-refundable milestone payment upon execution of the Materials Transfer Agreement (MTA). Future revenue will be generated via a transfer fee based on Novavax's production costs and potential per-dose payments under a future Distribution Agreement.
- Cost Allocation: Avimex covers passthrough and site costs for the first 1,000 clinical trial subjects plus other development costs up to a maximum. Novavax covers costs for additional subjects and all CRO costs.
Material Changes and Agreement Terms
On October 19, 2009, Novavax entered into an MTA to transfer 2009 H1N1 influenza vaccine to Avimex for clinical trials in Mexico. Key terms include:
- Clinical Trial Scope: Avimex will conduct trials using the vaccine. Novavax retains control over regulatory strategy decisions.
- Option to Distribute: Novavax granted Avimex an irrevocable option to enter a non-exclusive distribution agreement for Mexico. Avimex must decide whether to exercise this option upon receipt of regulatory approval or by December 31, 2009.
- Expiration: The MTA expires on December 31, 2009, unless the distribution option is exercised, extending it to December 31, 2010.
- Termination: Either party may terminate for material breach, felony conviction, or bankruptcy. If terminated by mutual agreement, Avimex must assist Novavax for 90 days.
Outlook, Risks, and Contingencies
Management Commentary: Novavax issued a press release on October 20, 2009, regarding the transaction and the upcoming clinical trial.
Risks and Contingencies:
- Regulatory Approval: Avimex is required to use commercially reasonable efforts to obtain regulatory approval in Mexico, but Novavax must approve all regulatory strategies.
- Option Exercise: If Avimex fails to exercise the distribution option by the deadline, or if Novavax seeks approval and Avimex does not cooperate, the option terminates. In specific termination scenarios involving a new distributor, Novavax may owe Avimex a fee.
- Data Rights: If the option is not exercised or the MTA is terminated for certain reasons, Novavax may use the clinical trial data globally and distribute the vaccine in Mexico.
Investor Verification Checklist
- Verify the exact amount of the fixed non-refundable milestone payment received from Avimex.
- Confirm the agreed maximum amount for development and regulatory costs covered by Avimex.
- Monitor the timeline for Avimex's decision to exercise the distribution option (deadline: December 31, 2009).
- Track the progress of the clinical trials in Mexico and the status of regulatory approval.
- Review the attached Distribution Agreement exhibit for specific per-dose transfer pricing details.